ArriVent BioPharma (NASDAQ:AVBP) Receives New Coverage from Analysts at HC Wainwright

Equities researchers at HC Wainwright started coverage on shares of ArriVent BioPharma (NASDAQ:AVBP) in a report released on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 53.00% from the company’s current price.

Several other research analysts also recently commented on AVBP. Jefferies Financial Group assumed coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They set a “buy” rating and a $35.00 target price on the stock. Citigroup initiated coverage on ArriVent BioPharma in a research note on Tuesday, February 20th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, The Goldman Sachs Group began coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $27.00 target price for the company.

ArriVent BioPharma Stock Up 5.8 %

AVBP stock opened at $16.34 on Tuesday. The company’s fifty day simple moving average is $18.39. ArriVent BioPharma has a 52-week low of $14.35 and a 52-week high of $25.95.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.